Advaxis Inc. (NASDAQ:ADXS)’s share price rose 1.9% on Thursday . The company traded as high as $11.83 and last traded at $11.75, with a volume of 213,703 shares. The stock had previously closed at $11.53.

ADXS has been the topic of a number of research analyst reports. FBR & Co reissued an “outperform” rating and issued a $34.00 price target on shares of Advaxis in a report on Tuesday, May 17th. HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Advaxis in a report on Thursday, June 9th. Jefferies Group reissued a “buy” rating on shares of Advaxis in a report on Friday, June 10th. Finally, Barclays PLC boosted their price target on shares of Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, August 3rd. Six research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $25.80.

The company’s 50 day moving average is $11.30 and its 200-day moving average is $9.04. The firm’s market cap is $404.60 million.

In other news, Director David Sidransky sold 22,808 shares of the firm’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total transaction of $342,348.08. Following the completion of the transaction, the director now directly owns 91,759 shares in the company, valued at $1,377,302.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard J. Berman sold 18,000 shares of the firm’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $15.21, for a total value of $273,780.00. Following the transaction, the director now owns 66,430 shares of the company’s stock, valued at $1,010,400.30. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.